TLR4 and neoplasm: Our previous finding supports the latter notion as patient‐derived tumors became sensitized to sorafenib when TIC's TLR4 signaling was attenuated.[48] A large effect (>60% reduction in tumor vol) was observed, and 10 mice/group achieved at least 88% power to establish a statistical difference using a one‐sided, 0.05‐level.